DK154418B - PROCEDURE FOR INCREASING THE QUANTITY SHARE OF A DESIRED ENANTIOMER OF A 2-ARYL PROPIC ACID - Google Patents
PROCEDURE FOR INCREASING THE QUANTITY SHARE OF A DESIRED ENANTIOMER OF A 2-ARYL PROPIC ACID Download PDFInfo
- Publication number
- DK154418B DK154418B DK100878AA DK100878A DK154418B DK 154418 B DK154418 B DK 154418B DK 100878A A DK100878A A DK 100878AA DK 100878 A DK100878 A DK 100878A DK 154418 B DK154418 B DK 154418B
- Authority
- DK
- Denmark
- Prior art keywords
- salt
- acid
- diluent
- process according
- enantiomer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
- C07C59/56—Unsaturated compounds containing hydroxy or O-metal groups containing halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
- C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
- C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
- C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
DK 154413BDK 154413B
Den foreliggende opfindelse angår fremstilling af optisk aktive 2-arylpropionsyrer, nærmere betegnet en fremgangsmåde til øgning af mængdeandelen af en ønsket enantiomer af en 2-arylpropionsyre som defineret i 5 krav 1's indledning. Visse 2-arylpropionsyrer vides at have værdifulde biologiske egenskaber, navnlig antiin-flammatoriske egenskaber.The present invention relates to the preparation of optically active 2-arylpropionic acids, more particularly to a method of increasing the amount of a desired enantiomer of a 2-arylpropionic acid as defined in the preamble of claim 1. Certain 2-arylpropionic acids are known to have valuable biological properties, particularly anti-inflammatory properties.
Det antages at hos nogle 2-arylpropionsyrer er den biologiske aktivitet af den ene af de optiske ιξοί 0 merer større end den biologiske aktivitet af dens enantiomer, og det er derfor ønskeligt at finde frem til en simpel fremgangsmåde til at opnå at den ene enantiomer fremhersker.It is believed that in some 2-arylpropionic acids, the biological activity of one of the optical ions is greater than the biological activity of its enantiomer, and it is therefore desirable to find a simple method to obtain the one enantiomer. .
Konventionel opspaltningsteknik, der indebærer 15 adskillelse af en blanding af diastereoisomere salte af en syre, er sædvanligvis meget besværlig og langsommelig fordi den ofte fordrer adskillige omkrystallisationstrin og tillige racemisering af den uønskede enantiomer for at forbedre udbytterne.Conventional cleavage technique involving separation of a mixture of diastereoisomeric salts of an acid is usually very cumbersome and slow because it often requires several recrystallization steps and also racemization of the undesirable enantiomer to improve yields.
20 Således beskriver fx britisk patentskrift nr.Thus, for example, British Patent Specification no.
1098878 og US patentskrift nr. 3686183 konventionelle resolveringsprocesser for arylalkyleddikesyrer. Fremgangsmåden ifølge nærværende opfindelse er ganske forskellig fra en konventionel resolveringsteknik der in-25 debærer separation af en blanding af diastereomere salte af en syre, både med hensyn til arbejdsbetingelser og med hensyn til den opnåede tekniske virkning.No. 1098878 and U.S. Patent No. 3686183 to conventional resolving processes for arylalkylacetic acids. The process of the present invention is quite different from a conventional resolution technique which involves separating a mixture of diastereomeric salts of an acid, both in terms of working conditions and in terms of the technical effect obtained.
Arbejdsbetingelserne ved en konventionel resolveringsteknik indebærer at man danner en varm fuldstæn-30 dig opløsning af de diastereomere salte og derpå afkøler opløsningen for at fremkalde fraktioneret krystallisation. I klar modsætning hertil foretager man ved den foreliggende fremgangsmåde - som nærmere forklaret senere i beskrivelsen - kontinuerlig opvarmning, der er 35 hele tiden en fast fase til stede og det faste produkt kan skilles fra den varme væskefase.The working conditions of a conventional resolving technique involve forming a hot complete solution of the diastereomeric salts and then cooling the solution to induce fractional crystallization. In contrast, in the present process - as explained later in the specification - continuous heating is carried out, a solid phase is present all the time and the solid product can be separated from the hot liquid phase.
Den opnåede tekniske virkning beskrives nærmere 2The technical effect obtained is described in more detail 2
DK 154418 BDK 154418 B
i slutningen af beskrivelsen.at the end of the description.
Der kendes også asymmetriske omlejringer, men hovedsagelig fra teoretiske og ikke fra praktiske synspunkter. Der er fx i "Molecular Asymmetry in Biology" 5 af Ronald Bentley, Academic Press 1969 s. 94-95 givet en teoretisk forklaring på asymmetriske omlejringer.Asymmetric rearrangements are also known, but mainly from theoretical and not practical points of view. For example, in "Molecular Asymmetry in Biology" 5 by Ronald Bentley, Academic Press 1969 pp. 94-95, a theoretical explanation of asymmetric rearrangements has been given.
Denne afhandling oplyser også at man opnår en stærkt højredrejende slutopløsning når dinitrofensyre opløses i alkohol og behandles med kinin, selv om udgangssyren 10 er optisk inaktiv og det naturlige alkaloid er stærkt venstredrejende. Der blev opnået resultater som tydede på at der kun var én diastereomer til stede, men alle forsøg på at regenerere en optisk aktiv form af dife-nylsyren mislykkede ’. Den nævnte afhandling hverken be-15 skriver eller foresrår således nogen praktisk fremgangsmåde til at opnå en ønsket enantiomer af en 2-arylpropionsyre.This thesis also states that a strongly right-turning final solution is obtained when dinitrophenic acid is dissolved in alcohol and treated with quinine, although the starting acid 10 is optically inactive and the natural alkaloid is strongly left-turning. Results were obtained suggesting that only one diastereomer was present, but all attempts to regenerate an optically active form of the diphenyl acid failed. Thus, said thesis does not describe or suggest any practical method for obtaining a desired enantiomer of a 2-arylpropionic acid.
Det har nu vist sig at en ønsket enantiomer af visse 2-arylpropionsyrer kan vindes fra en blanding af 20 diastereoisomere salte på simpel måde hvori der i almindelighed er involveret færre trin end ved konventionel spaltningsteknik. Fremgangsmåden ifølge opfindelsen er ejendommelig ved det i krav 1's kendetegnende del angivne.It has now been found that a desired enantiomer of certain 2-arylpropionic acids can be obtained from a mixture of 20 diastereoisomeric salts in a simple manner in which fewer steps are generally involved than in conventional cleavage technique. The process according to the invention is characterized by the characterizing part of claim 1.
25 Fremgangsmåden ifølge opfindelsen er særlig an vendelig på 2-(2-fluor-4-bifenylyl)-propionsyre og særligt med henblik på at opnå overvægt af (+)-isomeren.The process of the invention is particularly applicable to 2- (2-fluoro-4-biphenylyl) propionic acid and particularly to obtain the excess weight of the (+) isomer.
Fremgangsmåden ifølge opfindelsen kan udføres ved at man bruger en racemisk 2-arylpropionsyre, enhver 30 enantiomer af en 2-arylpropionsyre eller blandinger der indeholder en overvægt af den ene af enantiomererne. I afhængighed af det særlige salt der anvendes kan processen resultere i en forøgelse af den ene eller den anden enantiomer af syren. Anvendelse af en racemisk 35 syre fører til dannelse af et salt der indeholder overvægt af den ene enantiomer af syren. Ved processen sker der ikke i alle tilfælde omdannelse af materiale såThe process of the invention can be carried out using a racemic 2-arylpropionic acid, any 30 enantiomer of a 2-arylpropionic acid, or mixtures containing an excess weight of one of the enantiomers. Depending on the particular salt used, the process can result in an increase of one or the other enantiomer of the acid. Use of a racemic 35 acid leads to the formation of a salt containing overweight of one enantiomer of the acid. In the process, transformation of material does not happen in all cases
DK 154418BDK 154418B
3 der opnås salt af udelukkende den ene enantiomer af syren, så det er ofte ønskeligt at underkaste det vund-ne materiale et minimalt antal, som regel ikke over to, konventionelle omkrystallisationstrin eller andre rens-5 ningsprocesser3, salt is obtained from only one enantiomer of the acid, so it is often desirable to subject the recovered material to a minimal number, usually not above two, conventional recrystallization steps or other purification processes.
Den ønskede syre kan udvindes fra saltet på konventionel måde, fx ved syrning af saltet med en fortyndet mineralsyre efterfulgt af ekstraktion fra den vandige blanding med et passende organisk opløsningsmidlet del. Omkrystallisation af syren kan bevirke yderligere forøgelse af den optiske renhed.The desired acid can be recovered from the salt in a conventional manner, for example by acidifying the salt with a dilute mineral acid followed by extraction from the aqueous mixture with a suitable organic solvent portion. Recrystallization of the acid can further enhance the optical purity.
Det vil forstås at valget af base afhænger af 2-arylpropionsyren. Valget af fortyndingsmiddel afhænger af 2-arylpropionsyren og basen.It will be appreciated that the choice of base depends on the 2-aryl propionic acid. The choice of diluent depends on the 2-aryl propionic acid and the base.
15 I almindelighed er basen en a-monosubstitueret alkylamin, fortrinsvis en α-monosubstitueret ætylamin, navnlig en α-fenylætylamin hvor fenylringen kan være substitueret med en eller flere grupper såsom alkyl, fx alkyl og især isopropyl; halogen som fx klor 20 eller fluor; alkoxy såsom C^_4 alkoxy, navnlig metoxy.In general, the base is an α-monosubstituted alkylamine, preferably an α-monosubstituted ethylamine, in particular an α-phenylethylamine, wherein the phenyl ring may be substituted by one or more groups such as alkyl, for example alkyl and especially isopropyl; halogen such as chlorine or fluorine; alkoxy such as C 1-4 alkoxy, especially methoxy.
Særligt foretrukne baser er (-)-a-metylbenzylamin og (-)-a-(2-metoxyfenyl)-ætylamin. Andre egnede baser er (-)-a-(4-isopropylfenyl)-ætylamin, (-)-a-(3-klorfenyl)-ætylamin, (-)-a-(4-fluorfenyl)-ætylamin, (-)-a-(3-25 fluorfenyl)-ætylamin, (-)-a-(2-fluorfenyl)-ætylamin, (-)-a-(2-klorfenyl)-ætylamin, (+)-a-(2-metoxyfenyl)-ætylamin, (-)-a-(2,6-dimetoxyfenyl)-ætylamin og også (+)-α-cyklohexylætylamin.Particularly preferred bases are (-) - α-methylbenzylamine and (-) - α- (2-methoxyphenyl) ethylamine. Other suitable bases are (-) - α- (4-isopropylphenyl) -ethylamine, (-) - α- (3-chlorophenyl) -ethylamine, (-) - α- (4-fluorophenyl) -ethylamine, (-) - α- (3-fluorophenyl) -ethylamine, (-) - α- (2-fluorophenyl) -ethylamine, (-) - α- (2-chlorophenyl) -ethylamine, (+) - α- (2-methoxyphenyl) -ethylamine, (-) - α- (2,6-dimethoxyphenyl) -ethylamine and also (+) - α-cyclohexylethylamine.
Fortrinsvis opvarmes blandingen af fortyndings-30 midlet og saltet til en temperatur på 95-130°C.Preferably, the mixture of the diluent and salt is heated to a temperature of 95-130 ° C.
Det foretrækkes at mængdeforholdet mellem saltet og fortyndingsmidlet er fra 1:5 til 1:15 vægt/rumfang (v/r).It is preferred that the amount ratio of the salt to the diluent be from 1: 5 to 1:15 weight / volume (v / r).
Fortrinvis er opløseligheden af saltet af den ra-35 cemiske syre i fortyndingsmidlet ved arbejdstemperaturen 0,5-2% v/r.Preferably, the solubility of the salt of the racemic acid in the diluent at the working temperature is 0.5-2% v / r.
Fortrinsvis er 50-98 vægt% af saltet, navnligPreferably, 50-98% by weight of the salt, in particular
DK 154418 BDK 154418 B
4 80-95% uopløst i fortyndingsmidlet ved arbejdstempera-turen.4 80-95% undissolved in the diluent at the working temperature.
Det inerte fortyndingsmiddel er en væske ved den temperatur til hvilken blandingen opvarmes, og det kan 5 bestå af en eller flere organiske forbindelser. Sædvanligvis har fortyndingsmidlet lav polaritet og kan fx indeholde en eller flere kulbrinter. Fortyndingsmidlet er fortrinsvis en blanding af kulbrinter som overvejende er alifatiske, og fortrinsvis har det kogepunkt i områ-10 det 110-135°C. Der kan indgå polære forbindelser i mængder på fx op til 1% i fortyndingsmidlet.The inert diluent is a liquid at the temperature to which the mixture is heated and may consist of one or more organic compounds. Usually, the diluent has low polarity and may for example contain one or more hydrocarbons. The diluent is preferably a mixture of hydrocarbons which are predominantly aliphatic, and preferably has a boiling point in the range of 110-135 ° C. Polar compounds may be present in amounts of, for example, up to 1% in the diluent.
Det foretrækkes at fortyndingsmidlet er et sådant at reaktionen kan gennmemføres under tilbagesvalingsbetingelser.It is preferred that the diluent is such that the reaction can be carried out under reflux conditions.
15 For at undgå dannelse af biprodukter kan det væ re ønskeligt at opvarmningen udføres under en inert atmosfære, fx nitrogen.In order to avoid by-product formation, it may be desirable for the heating to be carried out under an inert atmosphere, e.g., nitrogen.
Fremgangsmåden ifølge opfindelsen skal i det følgende belyses nærmere vt_d nogle eksemler; i disse står 20 ordet flurbiprofen for (+)-2-(2-fluor-4-bifenylyl)-pro- pionsyre. Med mindre andet er angivet er specifikke drejninger målt i ætanol ved en koncentration på 1% v/r og ved stuetemperatur.The method according to the invention will now be elucidated in more detail below some examples; in these, the word flurbiprofen stands for (+) - 2- (2-fluoro-4-biphenylyl) propionic acid. Unless otherwise specified, specific turns are measured in ethanol at a concentration of 1% v / r and at room temperature.
25 Eksempel 1-31Examples 1-31
Forskellige blandinger indeholdende et aminsalt af en 2-arylpropionsyre og et fortyndingsmiddel bestående af en eller flere flydende organiske forbindelser 2g blev omrørt og opvarmet. Ved afslutningen af opvarmningen filtreredes de varme blandinger gennem en dampopvarmet Buchner-tragt og saltene vaskedes med det varme fortyndingsmiddel, tørredes i vakuum og syrnedes med tyndt svovlsyre eller saltsyre, hvorpå de sure blandinger ek- straheredes med æter. Æterekstrakterne vaskedes med vand, j 5 tørredes og inddampedes og gav 2-arylpropionsyrer med en anden optisk aktivitet end syrekomponenten af saltet fra 5Various mixtures containing an amine salt of a 2-arylpropionic acid and a diluent consisting of one or more liquid organic compounds 2g were stirred and heated. At the end of the heating, the hot mixtures were filtered through a steam-heated Buchner funnel and the salts washed with the hot diluent, dried in vacuo and acidified with thin sulfuric acid or hydrochloric acid, and the acidic mixtures extracted with ether. The ether extracts were washed with water, dried and evaporated to give 2-arylpropionic acids with a different optical activity than the acid component of the salt from 5
DK 15441S BDK 15441S B
frasøgets begyndelse.the beginning of the search.
Detaljerne af resultaterne af de forskellige eksempler fremgår af tabel I.The details of the results of the various examples are shown in Table I.
5 10 15 20 25 30 35 65 10 15 20 25 30 35 6
DK 154418 BDK 154418 B
73 {—> i—1 i—1 i—' i—1 i— f—1 i— i— f— m~"73 {-> i — 1 i — 1 i— 'i — 1 i— f — 1 i— i— f— m ~ "
MM
• ΗΗΜΜΜΜΜΙΟΜΜΜΜΜ H* h h to to ·<! _______.__ro gtfOØOO^OOGOOGOO^EOOO > M 3 H- _ 3 itfSdKXsisifdCidiaai-acnitfSjtfStfitfSdia 3 Pi 3i l_i μ- μ- o• ΗΗΜΜΜΜΜΙΟΜΜΜΜΜ H * h h to to · <! _______.__ ro gtfOØOO ^ OOGOOGOO ^ EOOO> M 3 H- _ 3 itfSdKXsisifdCidiaai-acnitfSjtfStfitfSdia 3 Pi 3i l_i μ- μ- o
ns Hns H
Pi<X3 <+Pi <X3 <+
ro ro >c Μ I 3 Iro ro> c Μ I 3 I
to g g ro μ- m I—1 I—· I—1 t—> I—1 t—1 I— I—1 [—· I—1 I—1 I—* E—1 1—1 I—1 t—1 I—* i—1 t—* HDi νοιϋοοοοοοοοοοοοοοοοοο r+QjHi - ro 0 45» it* M3 ft tJ 'C 3 3 • Oito gg ro µ- m I — 1 I— · I — 1 t—> I — 1 t — 1 I— I — 1 [- · I — 1 I — 1 I— * E — 1 1—1 I — 1 t — 1 I— * i — 1 t— * HDi νοιϋοοοοοοοοοοοοοοοοοο r + QjHi - ro 0 45 »it * M3 ft tJ 'C 3 3 • Oi
Πιο 3 G3ιο 3 G
ro i-3 i ro tr ---- — - φro i-3 i ro tr ---- - - φ
g O M H* to O Mg O M H * to O M
m 3 ro ro *3m 3 ro ro * 3
\ DJ ft Hi Η Η H\ DJ ft Hi Η Η H
MM MM CO M MM MMMiQrtOrt1©.MM MM CO M MM MMMiQrtOrt1 ©.
lOoiMLniotocoOUiooaiMtoioooooMtftf (D <5 3 cn 4^θ4^-ο>ϋ»ι^ωίοίοσ>θ3ϋΐσ>οοοαιοοο grortrorolOoiMLniotocoOUiooaiMtoioooooMtftf (D <5 3 cn 4 ^ θ4 ^ -ο> ϋ »ι ^ ωίοίοσ> θ3ϋΐσ> οοοαιοοο grortroro
- «. Cbk! Hi M- «. CBK! Hi M
Ui (0 3 3- 3 3 Ρ·~ιΡ ro ro H+ 3* t+ ro 3 ^ (0 3 WiQ I &Ui (0 3 3- 3 3 Ρ · ~ ιΡ ro ro H + 3 * t + ro 3 ^ (0 3 WiQ I &
3 <+ 0) W3 <+ 0) W
ro μ* g ‘c ro 3 I M 3 Hl & ro __I_ro µ * g 'c ro 3 I M 3 Hl & ro __I_
Ort rt 53 MMMMMMMM MMMMMMMMMMM 0(1)3-(0 MMMtOtOtOMMCOOMMMMMMMMMM g O ff (jicncnaicntjiCTicnOOOtOOOUicnCTicncncncn *α ΰ i*r*Location rt 53 MMMMMMMM MMMMMMMMMMM 0 (1) 3- (0 MMMtOtOtOMMCOOMMMMMMMMMM g O ff (jicncnaicntjiCTicnOOOtOOOUicnCTicncncncn * α ΰ i * r *
• (o tf 1 3-I• (o tf 1 3-I
tf o Vtf o V
H· 3 ro -J -J s] ΰ vjvJOOO'JOOO-O'-J-JOtO g ro roH · 3 ro -J -J s] ΰ vjvJOOO'JOOO-O'-J-JOtO g ro ro
totototooioototototototototocototototoi^ (D rt· JVtotototooioototototototototocototototoi ^ (D rt · JV
3 3- tf3 3- tf
Pi μ-Pi µ-
- I- I
—— p, α—— p, α
OlOOO^l'JOrf^Ol'JO-O-O-OOlOiyiOlOO'-JUl Hipi |it!»4i.(T>0(OM'43CTl<I<3lCnlti.(OlOMMMOMOO <#P tf ouioocnoouiocntocntooototoooo ro tf M riet- ro ro 3 —< + 1+ + + + + + + + + + + + + + + + + + kjpip (04^(OCOCOtOCOIOMtOtOU)(OtOtOiOU)(OU)tO 3 <! —11 OMtOCnCOtO^JOCnCnCO(OlO-^liti»CDiJ^MUllO (D 30 * 3 iofc^j!.(naiomoouiiii.ot>(BWU[owu(n p· ro UI o ro Hl _ I_rt 7OlOOO ^ l'JOrf ^ Ol'JO-OO-OOlOiyiOlOO'-JUl Hipi | it! »4i. (T> 0 (OM'43CTl <I <3lCnlti. (OlOMMMOMOO <#P tf ouioocnoouiocntocntooototoooo ro tf M riet- ro ro 3 - <+ 1+ + + + + + + + + + + + + + + + + kjpip (04 ^ (OCOCOtOCOIOMtOtOU) (OtOtOiOU) (OU) tO 3 <! -11 OMtOCnCOtO ^ JOCnCnCO (OlO- ^ liti »CDiJ ^ MUllO (D 30 * 3 iofc ^ j !. {naiomoouiiii.ot> {BWU [owu (np · ro UI o ro Hl _ I_rt 7
DK 154418 BDK 154418 B
UWtOWlOIOMWtON) tO MUWtOWlOIOMWtON) tO M
HO'noo-JcricnJ^ojNJi-1 ^ in t Η Η Η Η Η H H tfc·HO'noo-JcricnJ ^ ojNJi-1 ^ in t Η Η Η Η Η H H tfc ·
HH
ΦΦ
Qn^OfSOQQOQ > ro 3 H· 3 N!d»)fdli)5cl(flHS)d5d 3 Dj Hi to Η H 0Qn ^ OfSOQQOQ> ro 3 H · 3 N! D ») fdli) 5cl (flHS) d5d 3 Dj Hi to Η H 0
Di 3 HTue 3 H
QjiQ rt ® 01^ Η I 3 w 3 3QjiQ rt ® 01 ^ Η I 3 w 3 3
p Η Hp Η H
H HH H Dj sjum^mmuiurnoo rt Di tftH HH H Dj sjum ^ mmuiurnoo rt Di tft
- - (D O- - (D O
tO Ό HHtO Ό HH
rt T3 H 3 • D.rt T3 H 3 • D.
HH
iQ 3iQ 3
iQiQ
tn t-3tn t-3
I PI P
trtr
-----(D----- (D
3 O Η H tn O H3 O Η H tn O H
H 3 (D HUH 3 (D HU
X m ft Ηι Η Η HX m ft Ηι Η Η H
Ι-j h iQ rt O rt "S.Ι-j h iQ rt O rt „S.
atouifrmmtoHuiuiH (D <! H 01 CatouifrmmtoHuiuiH (D <! H 01 C
O OOrOOOO'iO'iOlOO'JO 3 fl> ft P ID ™ Ό DiHJ HiH oO OOrOOOO'iO'iOlOO'JO 3 fl> ft P ID ™ Ό DiHJ HiH o
(ji (D 3 Η H(ji (D 3 Η H
Η H Di~iQ (+Di H Di ~ iQ (+
P (D H|+ 3* WP (D H | + 3 * W
rt P 3 —' (D Prt P 3 - '{D P
C ?T<D I Di t+ H r+ tn tn ^C? T <D I Di t + H r + tn tn ^
ro h 3 *·< Pro h 3 * · <P
3 I Η- H Hi3 I Η- H Hi
Di Φ __I_Di Φ __I_
Ort rt Jt) |_i|_i(_i|_i(_il-i(_iHHHH O (D Η ΦLocation rt Jt) | _i | _i (_i | _i (_il-i (_iHHHH O (D Η Φ
HHHHHHHHHHH 3 O PHHHHHHHHHHH 3 O P
WUlWUlWUl'J'lUlMUl Ό 3 TTWUlWUlWUl'J'lUlMUl TT 3 TT
• tn rt i μ·• tn rt in μ ·
__I__IN
rt 0 W η 3 ro 3 W Prt 0 W η 3 ro 3 W P
tototototototototototo Φ rttotototototototototototo Φ rt
Η H rt Di H - IΗ H rt Tue H - I
P CP C
wmuiuitBffi'JCOijimoo t*1 Pj 'juioo^jororo^a^jcno ^ Cf CO *s vjji.ooiHuioO'Jom Prt H rt rt ro * tn 3 —’wmuiuitBffi'JCOijimoo t * 1 Pj 'juioo ^ jororo ^ a ^ jcno ^ Cf CO * s vjji.ooiHuioO'Jom Prt H rt rt ro * tn 3 -'
+ + + + + I+ + + + + ^ Q1 P+ + + + + I + + + + + ^ Q1 P
tOtOJ^-JtOUlLnUl-JtOUl ro DOtOtOJ ^ -JtOUlLnUl-JtOUl ro DO
U)(7lVDaiHtOrfitj0U)*>.O PU) (7lVDaiHtOrfitj0U) *>. O P
__rt 8__rt 8
DK 154418 BDK 154418 B
Nøgle til tabel IKey to Table I
2-arylpropionsyrer2-arylpropionic acids
Al = (+)-2-(2-fluor-4-bifenylyl)-propionsyre ♦'Λ A2 = 2-(2-fluor-4-bifenylyl)-propionsyre med optisk e r i _ onO rene iso- ^ \ merer af A3 = 2-(2-fluor-4-bifenylyl)-propionsyre med Yflurbipro- r t .Λ _o / fen har [a]„ = -44,7 i r i o , D ' [aJD pa + A4 = 2-(2-fluor-4-bifenylyl)-propionsyre med j eller [«]D = +8,9° J -44'7 10 B = (+)-2-(2'-fluor-4-bifenylyl)-propionsyre: optisk ren ( + )-isomer har [cx]^ = +50,3° C = ( + )-2-(2,2',4 *-trifluor-4-bifenylyl)-propionsyre: optisk ren ( + '-isomer har [oc]D = +35,9° 15 D = (+)-2-(6-metoxy-2-naftyl)-propionsyre: optisk ren (+)-isomer har [a]D = +66° E = (+)-2-[4-(2-fluorfenoxy)-fenyl]-propionsyre: optisk ren (+)-isomer har Ια]β = +42,0° F = (+)-2-(2-hydroxy-4-bifenylyl)-propionsyre: optisk 20 ren (+)-isomer har [a]D = +47,6° x Specifik drejning af. denne syre måltes i kloroform ved en koncentration på 1% v/r.Al = (+) - 2- (2-fluoro-4-biphenylyl) -propionic acid = 2- (2-fluoro-4-biphenylyl) -propionic acid with Yflurbiproprot. OO / phen has [α] + = -44.7 irio, D '[αJD pa + A 4-biphenylyl) propionic acid with j or [«] D = + 8.9 ° J -44'7 B = (+) - 2- (2'-fluoro-4-biphenylyl) propionic acid: optically pure (+ ) -isomer has [cx] + = + 50.3 ° C = (+) -2- (2,2 ', 4 * -trifluoro-4-biphenylyl) propionic acid: optically pure (+' isomer has [o ] D = + 35.9 ° D = (+) - 2- (6-methoxy-2-naphthyl) propionic acid: optically pure (+) - isomer has [a] D = + 66 ° E = (+) -2- [4- (2-fluorophenoxy) -phenyl] -propionic acid: optically pure (+) - isomer has Ια] β = + 42.0 ° F = (+) - 2- (2-hydroxy-4-biphenylyl) ) -propionic acid: optically pure (+) - isomer has [a] D = + 47.6 ° x Specific rotation of this acid was measured in chloroform at a concentration of 1% v / r.
Aminer 25 G = (-)-a-metylbenzylamin H = (-)-a-(4-isopropylfenyl)-ætylamin J = (+)-a-cyklohexylætylamin K = (-)-a-(3-klorfenyl)-ætylamin L1 = (+)-a-(2-metoxyfenyl)-ætylamin 30 L2 = (-)-a-(2-metoxyfenyl)-ætylamin M = (-)-a-(4-fluorfenyl)-ætylamin N = (+)-a-(2-fluorfenyl)-ætylamin O = (-)-a-(2-klorfenyl)-ætylamin P = (-)-a-(3-fluorfenyl)-ætylamin 35Amines G = (-) - α-methylbenzylamine H = (-) - α- (4-isopropylphenyl) -ethylamine J = (+) - α-cyclohexylethylamine K = (-) - α- (3-chlorophenyl) -ethylamine L1 = (+) - α- (2-methoxyphenyl) -ethylamine L2 = (-) - α- (2-methoxyphenyl) -ethylamine M = (-) - α- (4-fluorophenyl) -ethylamine N = (+ ) -a- (2-fluorophenyl) -ethylamine O = (-) - α- (2-chlorophenyl) -ethylamine P = (-) - α- (3-fluorophenyl) -ethylamine 35
DK 154418 BDK 154418 B
99
Opløsningsmidler R = jordoliefraktion, begyndelseskogepunkt 112°C S = (-)-a-pinen T = myrcen 5 U1 = 85% R + 15% toluen U2 = 67% R + 33% toluen V = jordoliefraktion, kogepunktsområde 120-160°C W = jordoliefraktion, begyndelseskogepunkt 125°C X = oktan 10 Y = jordoliefraktion, begyndelseskogepunkt 115°C, indeholdende 1% n-butanol Z = toluenSolvents R = petroleum fraction, initial boiling point 112 ° CS = (-) - α-pinene T = myrcene 5 U1 = 85% R + 15% toluene U2 = 67% R + 33% toluene V = petroleum fraction, boiling range 120-160 ° CW = petroleum fraction, initial boiling point 125 ° CX = octane 10 Y = petroleum fraction, initial boiling point 115 ° C, containing 1% n-butanol Z = toluene
Eksempel 32 15 4,75 kg flurbiprofen blandedes med 48 liter af en jordoliefraktion med kp. 125°C og blandingen omrør-tes under nitrogen og opvarmedes til dannelse af en opløsning. Der tilsattes under omrøring 2,35 kg (-)-cc-2Q metylbenzylamin i 23 liter af samme jordoliefraktion og blandingen opvarmedes derefter under tilbagesvaling under nitrogen i 72 timer. Den indre temperatur var 125°C.Example 32 15 4.75 kg of flurbiprofen was mixed with 48 liters of a petroleum fraction with kp. 125 ° C and the mixture is stirred under nitrogen and heated to form a solution. 2.35 kg of (-) - cc-2Q methylbenzylamine in 23 liters of the same petroleum fraction was added with stirring and then the mixture was heated under reflux under nitrogen for 72 hours. The internal temperature was 125 ° C.
Derpå filtreredes blandingen og saltet vaskedes med den varme benzin og tørredes og gav 5,4 kg af (-)-a-metyl-25 benzylaminsaltet af 2-(2-fluor-4-bifenylyl)-propionsy-re, svarende til et udbytte på 76%. En lille portion af dette syrnedes og gav 2-(2-fluor-4-bifenylyl)-pro-pionsyre med [cc]D = +33°. Resten omkrystalliseredes fra isopropanol og en portion syrnedes og gav 2-(2-fluor-4-bifenylyl)-propionsyre med [a]D = +41°.Then the mixture was filtered and the salt washed with the hot gasoline and dried to give 5.4 kg of the (-) - α-methyl-benzylamine salt of 2- (2-fluoro-4-biphenylyl) propionic acid, corresponding to a yield of 76%. A small portion of this was acidified to give 2- (2-fluoro-4-biphenylyl) propionic acid with [cc] D = + 33 °. The residue was recrystallized from isopropanol and a portion was acidified to give 2- (2-fluoro-4-biphenylyl) propionic acid with [α] D = + 41 °.
Resten af det omkrystalliserede salt (4,3 kg) blandedes med 35 liter petroleumsæter (kp. 102-120°C) og 37 liter vand og blandingen omrørtes under nitrogen.The rest of the recrystallized salt (4.3 kg) was mixed with 35 liters of petroleum ether (bp 102-120 ° C) and 37 liters of water and the mixture was stirred under nitrogen.
Der tilsattes 1 kg koncentreret saltsyre og blandingen 35 kogtes under tilbagesvaling i 1 time. Det varme organiske lag fraskiltes, vaskedes med vand, filtreredes og afkøledes og produktet opsamledes ved filtrering, va-1 kg of concentrated hydrochloric acid was added and the mixture was refluxed for 1 hour. The hot organic layer was separated, washed with water, filtered and cooled and the product collected by filtration,
DK 154418 BDK 154418 B
10 skedes med hexan og tørredes og gav 2-(2-fluor-4-bife-nylyl)-propionsyre med [a]D = +43,7°, svarende til 98% optisk renhed.10 was separated with hexane and dried to give 2- (2-fluoro-4-biphenyllyl) propionic acid with [α] D = + 43.7 °, corresponding to 98% optical purity.
Filtratet efter de oprindelige 72 timers opvarm-5 ning af saltet sammen med fast stof udvundet fra moderluden fra isopropanolomkrystallisationen af saltet og benzinkrystallisationen med syren recirkuleredes alle til behandling med en yderligere mængde flurbiprofen.The filtrate after the initial 72 hours of heating the salt together with the solid recovered from the mother liquor from the isopropanol recrystallization of the salt and the gasoline crystallization with the acid were all recycled for treatment with an additional amount of flurbiprofen.
Aminsaltet af den racemiske syre havde en oplø-10 selighed i jordoliefraktionen på 124 ml/g ved 125°C.The amine salt of the racemic acid had a solubility in the petroleum fraction of 124 ml / g at 125 ° C.
Eksempel 33 1 Vægtdel af (-)-a-metylbenzylammoniumsaltet af .jt- flurbiprofen blandedes med 10 rumfangsdele petroleumsæter (kp. 40-60°C) og opvarmedes til 116°C i en lukket autoklav i 72 timer. Derefter afkøledes blandingen og filtreredes og saltet vaskedes med petroleumsæter og tørredes i vakuum; der fremkom 93,5% udbytte af et salt 2q som gav 2-(2-fluor-4-bifenylyl)-propionsyre med [oc]D = +21,9°.Example 33 1 Weight portion of the (-) - α-methylbenzylammonium salt of the γ-flurbiprofen was mixed with 10 volumes of petroleum ether (b.p. 40-60 ° C) and heated to 116 ° C in a closed autoclave for 72 hours. Then the mixture was cooled and filtered and the salt washed with petroleum ether and dried in vacuo; 93.5% yield of a salt 2q was obtained which gave 2- (2-fluoro-4-biphenylyl) propionic acid with [oc] D = + 21.9 °.
Teknisk virkningTechnical effect
Af de data der er anført i foranstående tabel I 2^ kan man beregne andelen af den dominerende enantiomer i den syre der udvindes i hvert enkelt forsøg, idet følgende ligning anvendtes: [ot]m + [ot]e % dominerende enantiomer i syren = -x 100 2 x [oc]e 30 hvor m er den optiske drejning af udvundet syre og e den optiske drejning af ren enantiomer Det er instruktivt at udtrykke procentdelen af den dominerende enantiomer i saltet (som selvsagt er 2^ identisk med procentdelen af den dominerende enantiomer i den udvundne syre) som procentudbyttet regnet ud fra den oprindelige vægt af syre; det gælder således at 1 1From the data listed in the preceding Table I 2, the proportion of the dominant enantiomer in the acid recovered in each experiment can be calculated using the following equation: [ot] m + [ot] e% dominant enantiomer in the acid = -x 100 2 x [oc] e 30 where m is the optical rotation of extracted acid and e the optical rotation of pure enantiomer It is instructive to express the percentage of the dominant enantiomer in the salt (which of course is 2 ^ identical to the percentage of the dominant enantiomer in the recovered acid) as the percent yield calculated from the original weight of acid; so that 1 1
DK 154418 BDK 154418 B
y - P x Sy - P x S
hvor Y er % udbytte af dominerende enantiomer i saltet, P er % dominerende enantiomer i saltet og 5 S er S udbytte af salt.where Y is% yield of dominant enantiomer in the salt, P is% dominant enantiomer in the salt and 5 S is S yield of salt.
Værdier af S (fra eksemplerne) og af P og Y er beregnet på den ovenfor beregnede måde og resultaterne anført i tabel II.Values of S (from the examples) and of P and Y are calculated in the manner calculated above and the results are given in Table II.
Det ses af tabel II at udbytterne af den domine-10 rende enantiomer generelt er over 50%. Dette står i udtalt modsætning til en konventionel resolveringsproces, hvor det maksimale teoretiske udbytte er 50%, regnet ud fra syrens oprindelige vægt.It can be seen from Table II that the yields of the dominant enantiomer are generally above 50%. This is in marked contrast to a conventional resolution process where the maximum theoretical yield is 50%, calculated from the original weight of the acid.
15 20 25 30 3515 20 25 30 35
DK 154418 BDK 154418 B
1212
Tabel IITable II
Eks. % Udbytte af % Dominerende % Udbytte af nr. salt (S) enantiomer i den dominerensaltet (P) de enantiomer _(Y)_ 5 1 58,0 76,4 44,3 2 71,0 89,5 63,5 3 80,0 85,0 68,0 4 61,2 88,3 54,0 5 61,3 82,8 50,7 10 6 71,0 84,7 60,1 7 69,0 88,9 61,3 8 73,3 87,4 64,0 9 74,5 86,9 64,7 10 75,3 87,4 65,8 15 11 76,5 78,5 60,1 12 77,0 67,7 52,1 13 66,5 80,9 53,8 14 49,0 91,4 44,8 15 71,0 75,2 53,4 20 16 73,5 87,6 64,4 17 70,0 89,6 62,7 18 76,0 86,2 65,5 19 84,3 96,4 81,2 20 64,0 91,7 58,7 25 21 80,5 89,1 71,7 22 66,0 86,2 56,9 23 67,7 70,7 47,9 24 87,0 87,3 75,9 25 79,0 89,6 70,8 30 26 69,5 89,4 62,1 27 80,1 97,1 77,8 28 57,6 92,1 53,0 29 58,0 89,0 51,6 30 65,4 65,0 42,5 35 31 57,7 83,9 48,4 32 76,0 86,9 66,0 33 _93,5_74,4_69,6Ex. % Yield of% Dominant% Yield of No. Salt (S) Enantiomer in the Dominant Salt (P) Enantiomer _ (Y) _ 5 1 58.0 76.4 44.3 2 71.0 89.5 63.5 3 80.0 85.0 68.0 4 61.2 88.3 54.0 5 61.3 82.8 50.7 10 6 71.0 84.7 60.1 7 69.0 88.9 61.3 8 73.3 87.4 64.0 9 74.5 86.9 64.7 10 75.3 87.4 65.8 15 11 76.5 78.5 60.1 12 77.0 67.7 52, 1 13 66.5 80.9 53.8 14 49.0 91.4 44.8 15 71.0 75.2 53.4 20 16 73.5 87.6 64.4 17 70.0 89.6 62 , 7 18 76.0 86.2 65.5 19 84.3 96.4 81.2 20 64.0 91.7 58.7 25 21 80.5 89.1 71.7 22 66.0 86.2 56.9 23 67.7 70.7 47.9 24 87.0 87.3 75.9 25 79.0 89.6 70.8 30 26 69.5 89.4 62.1 27 80.1 97, 1 77.8 28 57.6 92.1 53.0 29 58.0 89.0 51.6 30 65.4 65.0 42.5 35 31 57.7 83.9 48.4 32 76.0 86 , 9 66.0 33 _93.5_74.4_69.6
Claims (8)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB969777 | 1977-03-08 | ||
GB9697/77A GB1596032A (en) | 1977-03-08 | 1977-03-08 | Resolution of optically active 2-arylpropionic acids |
GB194678 | 1978-01-18 | ||
GB194678 | 1978-01-18 |
Publications (3)
Publication Number | Publication Date |
---|---|
DK100878A DK100878A (en) | 1978-09-09 |
DK154418B true DK154418B (en) | 1988-11-14 |
DK154418C DK154418C (en) | 1989-06-19 |
Family
ID=26237091
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK100878A DK154418C (en) | 1977-03-08 | 1978-03-07 | PROCEDURE FOR INCREASING THE QUANTITY SHARE OF A DESIRED ENANTIOMER OF A 2-ARYL PROPIC ACID |
Country Status (29)
Country | Link |
---|---|
JP (1) | JPS53112841A (en) |
AT (1) | AT360508B (en) |
AU (1) | AU521708B2 (en) |
BG (1) | BG28567A3 (en) |
CA (1) | CA1105942A (en) |
CH (1) | CH638482A5 (en) |
CS (1) | CS222255B2 (en) |
DD (1) | DD136261A5 (en) |
DE (1) | DE2809794A1 (en) |
DK (1) | DK154418C (en) |
EG (1) | EG13345A (en) |
ES (1) | ES467606A1 (en) |
FI (1) | FI66828C (en) |
FR (1) | FR2383155A1 (en) |
GR (1) | GR64816B (en) |
HU (1) | HU178810B (en) |
IE (1) | IE46476B1 (en) |
IN (1) | IN147834B (en) |
IT (1) | IT1202818B (en) |
LU (1) | LU79186A1 (en) |
NL (1) | NL189126C (en) |
NO (1) | NO146197C (en) |
NZ (1) | NZ186644A (en) |
PH (1) | PH13333A (en) |
PL (1) | PL110888B1 (en) |
PT (1) | PT67743A (en) |
SE (1) | SE436422B (en) |
SU (1) | SU784759A3 (en) |
YU (1) | YU41472B (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2826952A1 (en) * | 1978-06-20 | 1980-01-10 | Bayer Ag | ENANTIOMER SEPARATION OF CHIRAL CARBONIC ACIDS |
PH15674A (en) * | 1979-07-06 | 1983-03-11 | Syntex Corp | Process for the resolution of d,1 2-(6-methoxy-2-naphthyl)propionic acid |
JPS57145830A (en) * | 1981-03-06 | 1982-09-09 | Hiroyuki Nohira | Optical resolution of 2-(4-chlorophenyl)-3-methylbutanoic acid |
JPH01126425U (en) * | 1988-02-23 | 1989-08-29 | ||
DE3824353A1 (en) * | 1988-07-19 | 1990-01-25 | Paz Arzneimittelentwicklung | METHOD FOR SEPARATING MIXED ENANTIOMER ARYLPROPIONIC ACIDS |
DE4028906A1 (en) * | 1990-09-12 | 1992-03-19 | Paz Arzneimittelentwicklung | MEDICINAL PRODUCTS AND THEIR PREPARATION AND THEIR USE IN THE CONTROL OF PAIN AND / OR DEFENSE AND / OR FEVER OF ANIMALS AND PEOPLE |
DE4319438C1 (en) * | 1993-06-11 | 1994-06-01 | Gerd Dr Dr Geislinger | Analgesic and/or antiinflammatory medicaments - contg. sepd enantiomers of ketoprofen |
JP3782834B2 (en) | 1994-10-26 | 2006-06-07 | 株式会社トクホン | Analgesic anti-inflammatory patch |
DE19717429A1 (en) | 1997-04-25 | 1998-12-24 | Bayer Ag | Production of enantiomerically pure biaryl ketocarboxylic acids |
EP2393771A1 (en) | 2009-02-06 | 2011-12-14 | DSM IP Assets B.V. | Method for the synthesis of chiral alpha-aryl propionic acid derivatives |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1098878A (en) * | 1964-05-07 | 1968-01-10 | Merck & Co Inc | d-4-phenyl-ª‡-methylphenylacetic acid and its derivatives and anti-inflammatory compositions containing such compounds and their racemic forms |
US3686183A (en) * | 1969-03-24 | 1972-08-22 | Syntex Corp | Preparation of optical isomers of arylalkylacetic acids |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2015728A1 (en) * | 1968-04-18 | 1970-04-30 | Lilly Co Eli | Anti-inflammatory substd-phenylalkanoic acids and - derivs |
-
1978
- 1978-03-06 PT PT67743A patent/PT67743A/en unknown
- 1978-03-06 GR GR55617A patent/GR64816B/en unknown
- 1978-03-06 CS CS781413A patent/CS222255B2/en unknown
- 1978-03-07 DE DE19782809794 patent/DE2809794A1/en active Granted
- 1978-03-07 IT IT48320/78A patent/IT1202818B/en active
- 1978-03-07 SE SE7802603A patent/SE436422B/en not_active IP Right Cessation
- 1978-03-07 ES ES467606A patent/ES467606A1/en not_active Expired
- 1978-03-07 FI FI780738A patent/FI66828C/en not_active IP Right Cessation
- 1978-03-07 NO NO780785A patent/NO146197C/en unknown
- 1978-03-07 CA CA298,426A patent/CA1105942A/en not_active Expired
- 1978-03-07 IE IE467/81A patent/IE46476B1/en not_active IP Right Cessation
- 1978-03-07 SU SU782588501A patent/SU784759A3/en active
- 1978-03-07 AT AT163478A patent/AT360508B/en not_active IP Right Cessation
- 1978-03-07 IN IN241/CAL/78A patent/IN147834B/en unknown
- 1978-03-07 YU YU540/78A patent/YU41472B/en unknown
- 1978-03-07 DK DK100878A patent/DK154418C/en not_active IP Right Cessation
- 1978-03-07 CH CH249378A patent/CH638482A5/en not_active IP Right Cessation
- 1978-03-07 HU HU78BO1703A patent/HU178810B/en unknown
- 1978-03-07 BG BG7838943A patent/BG28567A3/xx unknown
- 1978-03-08 JP JP2644878A patent/JPS53112841A/en active Granted
- 1978-03-08 NZ NZ186644A patent/NZ186644A/en unknown
- 1978-03-08 LU LU79186A patent/LU79186A1/en unknown
- 1978-03-08 AU AU33977/78A patent/AU521708B2/en not_active Expired
- 1978-03-08 FR FR7806692A patent/FR2383155A1/en active Granted
- 1978-03-08 DD DD78204036A patent/DD136261A5/en unknown
- 1978-03-08 PL PL1978205161A patent/PL110888B1/en unknown
- 1978-03-08 NL NLAANVRAGE7802520,A patent/NL189126C/en not_active IP Right Cessation
- 1978-03-11 EG EG161/78A patent/EG13345A/en active
- 1978-03-13 PH PH20873A patent/PH13333A/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1098878A (en) * | 1964-05-07 | 1968-01-10 | Merck & Co Inc | d-4-phenyl-ª‡-methylphenylacetic acid and its derivatives and anti-inflammatory compositions containing such compounds and their racemic forms |
US3686183A (en) * | 1969-03-24 | 1972-08-22 | Syntex Corp | Preparation of optical isomers of arylalkylacetic acids |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2021517901A (en) | Preparation of racemic nicotine by reaction of ethyl nicotinate with N-vinylpyrrolidone in the presence of an alcoholate base and subsequent steps | |
US4209638A (en) | Preparation of therapeutic agents | |
JP6912664B2 (en) | Process for preparing tapinarov | |
DK154418B (en) | PROCEDURE FOR INCREASING THE QUANTITY SHARE OF A DESIRED ENANTIOMER OF A 2-ARYL PROPIC ACID | |
CN1069312C (en) | Substituted imidogen sulfamide, its preparation, use and medicines containing the same | |
JP2016121196A5 (en) | ||
US8703955B2 (en) | Process for the resolution of isoquinoline derivatives | |
KR20150118146A (en) | Vortioxetine manufacturing process | |
US20220162154A1 (en) | D-metyrosine compositions and methods for preparing same | |
NO861988L (en) | INTERMEDIATES FOR THE PREPARATION OF NEW SUBSTITUTED HETEROCYCLIC PHENOXYAMINES AND PROCEDURES FOR THE PREPARATION OF THEREOF. | |
JP4451600B2 (en) | Method for producing biperiden | |
JP6446464B2 (en) | Method for producing pyrazole derivative | |
TW201504215A (en) | Method for producing pyridazine compound | |
JPS5940155B2 (en) | Method for producing 4-oxohexahydropyrazinoisoquinoline derivative | |
JP5714213B2 (en) | Racemic separation of 2,6-trans-dimethylmorpholine | |
JP6919733B2 (en) | Method for producing propionic acid derivative | |
JP2009526048A (en) | Preparation of 7-alkenyl-3quinolinecarbonitrile via palladium mediated coupling reaction | |
JPH1036327A (en) | Production of optically active isomer of 1-(3-methoxyphenyl)ethylamine | |
JPS5931741A (en) | Secoverine (+) s enantiomer and salt, manufacture and antispasmodic | |
JPH10251233A (en) | Production of methylquinolines | |
Hashimoto et al. | Asymmetric Synthesis of a Xanthine Dehydrogenase Inhibitor (S)-(–)-BOF-4272: Mechanism of Chiral Diaryl Sulfoxide Formation | |
DK153142B (en) | METHOD OF ANALOGUE FOR THE PREPARATION OF O-AMINOAL COXY-SUBSTITUTED DIBENZYLETHERS OR PHARMACOLOGICAL ACCEPTABLE SALTS THEREOF | |
PL84252B1 (en) | (cyano methylphenoxy) hydroxy alkylamino - propanes for coronary disease and hypertonia [DE1950351A1] | |
DK160495B (en) | BENZHYDRYLPIPERAZINE DERIVATIVES, A PROCESS FOR THE PREPARATION OF THESE, PHARMACEUTICAL PREPARATIONS CONTAINING THESE, AND A PROCEDURE FOR PROMOTING SUCH PHARMACEUTICAL PREPARATIONS | |
US7034162B2 (en) | Amorphous form of 3-[2-(dimethylamino) ethyl]-N-methyl-1H-indole-5-methane sulfonamide succinate (sumatriptan succinate) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUP | Patent expired |